Goldman Sachs Group Inc Lian Bio Transaction History

Goldman Sachs Group Inc

  • $580 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$0.3 - $4.99 $4,386 - $72,958
14,621 New
14,621 $4,000
Q3 2022

May 14, 2024
BUY
$1.87 - $3.0 $22,733 - $36,471
12,157 New
12,157 $24,000
Q3 2022

Nov 10, 2022
BUY
$1.87 - $3.0 $22,733 - $36,471
12,157 New
12,157 $24,000
Q2 2022

Aug 15, 2022
SELL
$2.15 - $6.01 $92,847 - $259,541
-43,185 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$2.8 - $6.21 $120,917 - $268,178
43,185 New
43,185 $160,000

Others Institutions Holding LIAN

# of Institutions
3
Shares Held
1.1M
Call Options Held
0
Put Options Held
0
View Full List

About LianBio

LIAN Quotes by TradingView
  • Ticker LIAN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,354,000
  • Market Cap $31.4M
  • Description
  • LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...
More about LIAN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email